My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Novartis AG Common Stock (NY:NVS)

131.26 -0.65 (-0.49%)

Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

38 39 Next >

Trump Unveils $200 Billion Trade Deal With Switzerland And Liechtenstein To Cull $38.5 Billion US Goods Deficit By 2028 ↗

November 15, 2025

President Donald Trump announced a framework for a trade deal with Switzerland and Liechtenstein on Friday.

Via Benzinga

Topics Government

AI Revolutionizes Drug Shelf-Life: Optimized Stability Models Promise Safer, More Effective Medicines

November 14, 2025

The pharmaceutical industry is on the cusp of a profound transformation, driven by the integration of data science and Artificial Intelligence (AI) into drug formulation stability models. This...

Via TokenRing AI

Topics Artificial Intelligence Economy Product Recall

Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025

November 14, 2025

The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Novartis Opens New Manufacturing Facility In California In Bid To Increase US Presence ↗

November 10, 2025

Via Stocktwits

AI Revolutionizes Cardiovascular Clinical Trials: A Leap Towards Cheaper, Faster Drug Development

November 13, 2025

San Francisco, CA – November 13, 2025 – Artificial Intelligence (AI) has achieved a pivotal breakthrough in the medical field, successfully adjudicating clinical events in cardiovascular trials. This...

Via TokenRing AI

Topics Artificial Intelligence

Novartis' Investigational Medicine Shows Potent Activity Against Drug-Resistant Malaria Strains ↗

November 13, 2025

Novartis' GanLum met key Phase 3 goals, showing strong efficacy and safety in malaria patients, including against resistant parasite strains.

Via Benzinga

Eledon Pharmaceuticals Stock Plunges Following $50 Million Public Offering

November 12, 2025

Irvine, CA – November 12, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a significant decline in its stock value today, plummeting by 17.8% in premarket trading. This sharp drop comes on the...

Via MarketMinute

Topics Initial Public Offering Intellectual Property Regulatory Compliance

Earnings Scheduled For October 28, 2025 ↗

October 28, 2025

Via Benzinga

AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps

November 10, 2025

The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable...

Via TokenRing AI

Topics Artificial Intelligence

AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns

November 05, 2025

Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design...

Via TokenRing AI

Topics Artificial Intelligence Intellectual Property

Celcuity Eyeing Cancer Treatment Riddle. Stock Flys 534% This Year. ↗

November 05, 2025

The company hopes to "solve a 20-year riddle" in cancer treatment. The journey has sent the biotech stock flying as much as 534%.

Via Investor's Business Daily

AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential

November 04, 2025

The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central...

Via TokenRing AI

Topics Artificial Intelligence

Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades ↗

November 03, 2025

Terns Pharmaceuticals shares rise after TERN-701 shows a 75% response rate in the CML trial, and William Blair upgrades the stock to Outperform.

Via Benzinga

iShares Core MSCI EAFE ETF (IEFA) Focuses on Developed Markets While Vanguard FTSE All-World ex-US ETF (VEU) Looks Globally ↗

November 03, 2025

iShares Core MSCI EAFE ETF (IEFA) Focuses on Developed Markets While Vanguard FTSE All-World ex-US ETF (VEU) Looks Globally

Via The Motley Fool

Topics ETFs

Trump Offers Help To 'Dilbert' Creator's Cancer Fight ↗

November 03, 2025

Trump offers help to cancer-stricken Dilbert creator Scott Adams after he appeals for assistance on social media. Adams seeks access to Pluvicto treatment for metastatic prostate cancer.

Via Benzinga

Topics Government

The Vanguard FTSE Developed Markets ETF (VEA) Offers Broader Diversification Than the SPDR Portfolio Developed World ex-US ETF (SPDW) ↗

November 02, 2025

The Vanguard FTSE Developed Markets ETF (VEA) Offers Broader Diversification Than the SPDR Portfolio Developed World ex-US ETF (SPDW)

Via The Motley Fool

Topics ETFs

Vanguard VEA ETF Boasts Broader Portfolio Than State Street's SPDR SPDW ↗

November 02, 2025

Vanguard VEA ETF Boasts Broader Portfolio Than State Street's SPDR SPDW

Via The Motley Fool

Topics ETFs

AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio

November 01, 2025

The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly...

Via TokenRing AI

Topics Animal Testing Artificial Intelligence Economy

The AI Imperative: Why Rapid Upskilling is Non-Negotiable for Pharma’s Future

October 31, 2025

The pharmaceutical sector stands at the precipice of a profound transformation, driven by the relentless march of artificial intelligence (AI) and other advanced technologies. As highlighted by...

Via TokenRing AI

Topics Artificial Intelligence Economy

AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs

October 31, 2025

San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of...

Via TokenRing AI

Topics Artificial Intelligence Supply Chain

AI Revolutionizes Pharma R&D: A New Era of Accelerated Drug Discovery and Personalized Medicine

October 31, 2025

Artificial intelligence (AI) is ushering in a transformative era for pharmaceutical research and development (R&D), fundamentally reshaping how new medicines are discovered, developed, and brought to...

Via TokenRing AI

Topics Artificial Intelligence Intellectual Property

AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future

October 31, 2025

The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late...

Via TokenRing AI

Topics Animal Testing Artificial Intelligence Economy

Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) ↗

October 31, 2025

Novartis is set to boost its developmental pipeline with this acquisition.

Via The Motley Fool

Here's My Favorite Passive Income Investment ↗

October 31, 2025

International dividend stocks are finally having their moment after years of underperformance, and this single Vanguard fund captures the opportunity with rock-bottom fees.

Via The Motley Fool

Topics ETFs

Is the Market Bullish or Bearish on Novartis AG? ↗

October 29, 2025

Via Benzinga

United Therapeutics Dips As Bread-And-Butter Drug Comes Up Short ↗

October 29, 2025

Shares of United Therapeutics slipped slightly Wednesday on light sales of its bread-and-butter drug, Tyvaso.

Via Investor's Business Daily

Novartis Slips As Generics Champ At Heart-Failure Drug In Mixed Third Quarter ↗

October 28, 2025

Generic competition had a 7 percentage-point negative impact on the company's biggest drug.

Via Investor's Business Daily

Novartis Maintains Outlook Even As Generics Bite Into Profits ↗

October 28, 2025

Novartis Q3 sales rose 8% to $13.91 billion, missing estimates, as Kisqali and Kesimpta drove growth while U.S. generics weighed on results.

Via Benzinga

'Merger Monday' Makes Comeback As US M&A Tops $80 Billion In 24 Hours ↗

October 28, 2025

U.S. companies have struck more than $80 billion worth of deals in the past 24 hours, in the latest sign that mergers and acquisitions (M&A) are picking up after the tariff-induced cool-off earlier...

Via Benzinga

Is It Too Late To Buy Avidity Stock After Novartis Deal? ↗

October 28, 2025

Novartis revealed plans of acquiring Avidity Biosciences Inc. in a $12 billion all-cash transaction. The announcement sent RNA shares soaring roughly 44% on Monday.

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.